8th Eurasian Hematology Oncology Summit
Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in 2021: Induction & Standard (VCD, VTD, VRd, Dara-VTD), Upfront ASCT vs. Bortezomib, Len Maintenance Until Progression
By
8th Eurasian Hematology Oncology Summit
FEATURING
Angelo Maiolino
By
8th Eurasian Hematology Oncology Summit
FEATURING
Angelo Maiolino
Login to view comments.
Click here to Login